Cladinose Analogues of Sixteen-membered Macrolide Antibiotics

III. Efficient Synthesis of 4-O-Alkyl-L-cladinose Analogues: Improved Antibacterial Activities Compatible with Pharmacokinetics

KEN-ICHI KURIHARA, NOBUE KIKUCHI and KEIICHI AJITO*

Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., Morooka-cho, Kohoku-ku, Yokohama 222, Japan

(Received for publication June 20, 1996)

The synthesis and biological evaluation of sixteen-membered macrolides possessing a 4-O-alkyl-α-L-cladinosyl moiety as a neutral sugar are described. These potent novel derivatives have been efficiently synthesized avoiding glycosylations. Two hydroxyl groups in mycarose of the tri-(tert-butyldimethylsilyl) ether intermediate were successively alkylated. Sequential deprotections of silyl groups afforded 4-O-alkyl-L-cladinose analogues and 3,4-di-O-alkyl-L-mycarose analogues of leucomycin V. Some 4-O-alkyl-L-cladinose analogues exhibited potent antibacterial activities. The most active derivative, 3"-O-methyl-4"-O-(3-methylbutyl)leucomycin V, showed improved metabolic stability in rat plasma in vitro and extremely high concentrations in serum after oral administrations in mice and in hamsters.

Sixteen-membered macrolide antibiotics¹⁾ are safe and useful in treating infections caused by Gram-positive bacteria and exert fewer interaction with other drugs and have less effect on the intestinal tract in comparison with the fourteen-membered macrolides. There seems to be some possibilities that their pharmacokinetics2) and therapeutic effects will be improved with chemical modifications. Kirst proposed several important factors for the improvement of macrolide antibiotics³⁾. Our work was focused on following two elements; 1) the improvement of chemical and metabolic stability, and 2) the improvement of serum concentrations. One explanation for the poor pharmacokinetics involves in vivo deacylation⁴⁾ at the neutral sugar moiety, which led us to design, synthesize and study of several stages of 4-O-alkyl-L-cladinose analogues (Fig. 1). As part of our program in this area, we have synthesized the 9-dehydro (a carbonyl group at the C-9 position) derivatives including compound (1) via glycosylations, and excellent metabolic stability of 1 was shown in rat plasma in vitro⁵⁾. Recently, we have also prepared the 9-OH derivatives, such as compound (2), using bioconversion, and dramatic improvement of pharmacokinetics was demonstrated⁶⁾. Sakakibara and Ōmura et al. have investigated many 3-OH derivatives of leucomycin, including rokitamycin (RKM), which is a very effective semi-synthetic sixteen-membered macrolide antibiotic. ^{7,8)}

In this paper, we wish to report the efficient synthesis of 3-OH derivatives (Fig. 1), such as compound $(3f)^{\dagger,9}$, a 4-O-alkyl-L-cladinose analogue of leucomycin V^{10} (LM-V) (Fig. 2), without glycosylation or biotransformation. The reported compound (3f) exhibited not only potent antibacterial activities *in vitro* but also

Fig. 1. 4-O-Alkyl-L-cladinose analogues of leucomycin.

[†] A compound (3f) was originally prepared *via* glycosylation and biotransformations. See ref. 9. The preparation of 3f using bioconversion will be reported elsewhere.

Fig. 2. A part of natural leucomycins and its analogue, RKM

excellent pharmacokinetics in spite of its 3-OH structure. Structure activity relationships (SAR) between the neutral sugars and antibacterial activities were also discussed.

When Sano, Ōmura *et al.* prepared 4"-O-substituted spiramycin I, a chemically stabilized silyl ether intermediate was used^{11,12}). Because there seemed to be some difficulties in introducing general alkyl groups^{††,13}) to hydroxyl groups of the neutral sugar moiety in leucomycins, 3, 18-(O-silyl)acetal protection could be desired. 4"-O-Methylation of erythromycin, however, has been already reported¹⁴). On the other hand, introducing a methyl group onto the tertiary hydroxyl group at C-3" position of a sixteen-membered macrolide antibiotic could be only done *via* glycosylation of a neutral sugar^{5,15}). It is mainly because the 3"-hydroxyl group seems to be highly hindered sterically in addition to its low reactivity¹²), that conversion of 3"-OH to 3"-OCH₃ has not been reported.

Chemistry

The *tert*-butyldimethylsilyl (TBS) protection of leucomycin A₇^{†††,16)} (LM-A₇) afforded tris-TBS ether (4) in a good yield. Selection of heterogeneous basic hydrolysis resulted in a quantitative chemoselective saponification at the C-4" position to generate diol (5). Fortunately, these conditions using phase transfer catalyst did not affect the lactone bond with a fused seven-membered silyl acetal ring.

Chemoselective 4"-O-alkylations were completed under rather strong conditions to afford the mono alkyl

Scheme 1. Synthesis of compounds $3a \sim 3g^{a,b}$.

Leucomycin A7

OTBS

a

$$CH_2$$
 CHOTBS

 $N(CH_3)_2$
 CH_3 O

 CH

^aReagents and conditions: (a) 6.0 equiv of TBSCl, 12 equiv of imidazole, DMF, 50°C, overnight, 83%; (b) 25% aqueous NaOH, 1.0 equiv of *n*-Bu₄NHSO₄, PhH-H₂O (2:1), 25°C, 2 h, 87%; (c) 30 equiv of alkyl halide, 5.0 equiv of NaH, DMF, 45°C, 1 h, 67-90%; (d) 1.5 equiv of *m*CPBA, CHCl₃, 25°C, 5 min; (e) 30 equiv of MeI, 5.0 equiv of NaH, 45°C 1 h; (f) silica gel, 25°C, overnight, 51-65% overall 3 steps; (g) 2.0 M of TBAF in THF, 45°C, 1 h, 54-94%. TBS: *tert*-Butyldimethylsilyl. ^bAlkyl side chains: (a) methyl; (b) ethyl; (c) *n*-propyl; (d) *n*-butyl; (e) *n*-pentyl; (f) 3-methylbutyl; (g) benzyl.

Some reactive alkylation (i.e. methoxymethyl or benzyl) did not require 3,18-(O-silyl)acetal protection. See ref. 13.

A large amount of LM-A₇ was produced from midecamycin A₁ via biotransformation using PF1083. See ref. 16. We are grateful to Drs. O. Hara, K. Uotani, S. Gomi and Mr. A. Shimizu for their useful suggestions and supports.

Fig. 3. Midecamycin A_3 and its derivative (11).

Scheme 2. Synthesis of compounds $20 \sim 22^a$.

^aReagents and conditions: (a) 30 equiv of alkyl iodide, 5.0 equiv of NaH, DMF, 45°C, 3-4 h; (b) 1.0 equiv of mCPBA, CHCl₃, 25°C, 5 min; (c) silica gel, 25°C, 3 days, 26, 25% overall 3 steps; (d) 2.0 M of TBAF in THF, 45°C, 1 h, 45-58%.

derivatives, compounds $(6b \sim 6g)$. A methyl group was then introduced at the tertiary hydroxyl group at the C-3" position (Scheme 1). First, direct methylation of 6 gave poor results because of the presence of a free dimethylamino group. Thus, an N-oxide intermediate of the dimethylamino group was used as follows: Oxidation of the dimethylamino group of 6 with mCPBA gave unstable N-oxides, compounds $(7b \sim 7g)$, quantitatively. Without purification at this stage, subsequent methylation exclusively proceeded at the 3"-alcohol to form 4-O-alkyl-L-cladinose moiety as a neutral sugar, accompanied with slight decomposition. In the case of introducing two methyl groups, the dimethylamino group of 5 was oxidized followed by dimethylation to give the compound (8a).

Fully protected unstable intermediates (8a~8g) were successively treated with gently acidic conditions (i.e. silica gel or diluted hydrochloric acid) to generate the free dimethylamino alcohol of the mycaminose moiety. Evidence of structure on compound (9f) was demonstrated by acetylation of 9f without any additional base to give its 2'-O-acetyl derivative (10) in a quantitative yield. Finally, deprotection of two TBS groups with exact 2.0 m of TBAF completed titled compounds $(3a \sim 3g)$ via acidic workups (see experimental). The above mentioned useful deprotection (compound (8) to (9)) could be observed in other substrates also. When unstable 2'-O-TBS midecamycin A₃ N-oxide (11) (Fig. 3) was treated with a mild acidic condition, midecamycin A₃ (a free dimethylamino alcohol) was mainly recovered as expected.

To investigate SAR of these molecules, especially at the neutral sugar moiety, we prepared another class of derivatives, **20** and **21** (Scheme 2). Alkylation (ethyl or *n*-propyl) at the 3"-OH group of **6f** proceeded in a moderate yield. Oxidation of the dimethylamino group allowed for chemoselective 2'-O-deprotection to generate the free dimethylamino alcohols, **17** and **18**. Finally, deprotection afforded compounds **20** and **21** possessing a totally unnatural neutral sugar. As a control material, 4-O-alkyl-L-mycarose analogue, compound (**22**), was also prepared by sequential deprotections of **6f** via **19** (Scheme 2).

Structures of these resulting antibiotic analogues $(3a \sim 3g)$ and $(20 \sim 22)$ were confirmed by ¹H NMR spectra (see experimental). The compounds (3f, 3g) were fully identified with those prepared *via* glycosylation and biotransformations previously⁹). The structure of the resulted neutral sugar was confirmed by acid hydrolysis. For example, treatment of 3f with p-toluenesulfonic acid and ethanol smoothly gave ethyl 4-O-(3-methylbutyl)- β -L-cladinoside⁵) with trace of its α -anomer.

Biological Evaluation

The antibacterial activities in vitro of novel 4-O-alkyl- α -L-cladinosyl derivatives $(3a \sim 3g)$ and the structurally related analogues $(20 \sim 22)$, compared with corresponding antibiotics which possess a free hydroxyl group at the C-3 position, are shown in Table 1. In the class of cladinose analogues $(3''\text{-OCH}_3)$, the activities of selected novel derivatives with suitable alkyl chain length $(C_3 \sim C_5$ and benzyl) were clearly improved based on that of

Table 1. Antibacterial activities of leucomycin derivatives and LM-A₇ (MIC, μg/ml).

Test organisms	3a	3 b	3c	3 d	3 e	3f	3 g	20	21	22	LM-A7	RKM
Staphylococcus aureus 209P JC-1	1.56	0.78	0.20	0.10	0.10	0.10	0.10	0.20	0.20	0.10	0.20	0.10
S. aureus M133	6.26	3.13	0.39	0.39	0.39	0.39	0.39	0.78	0.78	0.39	0.39	0.39
S. aureus M126	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
S. aureus MS15026	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
S. aureus MS15027	12.5	6.25	0.39	0.39	0.39	0.39	0.20	0.39	0.39	0.39	0.39	0.78
S. epidermidis ATCC14990	12.5	6.25	0.39	0.39	0.39	0.39	0.20	0.78	0.78	0.39	0.39	0.78
Micrococcus luteus ATCC9341	0.78	0.20	0.05	0.05	0.05	0.05	0.05	0.05	0.10	0.05	0.05	0.05
Enterococcus faecalis W-73	3.13	3.13	0.78	0.78	0.39	0.39	0.39	0.78	0.78	0.39	0.78	0.39
Streptococcus pneumoniae IP692	1.56	0.78	0.20	0.10	0.05	0.10	0.10	0.20	0.20	0.10	0.20	0.10
S. pneumoniae Type I	1.56	0.78	0.20	0.20	0.20	0.10	0.10	0.20	0.20	0.10	0.20	0.10
S. pyogenes Cook	1.56	0.78	0.10	0.10	0.10	0.05	0.10	0.10	0.10	0.10	0.10	0.05
Escherichia coli NIHJ JC-2	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
Klebsiella pneumoniae PC1602	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
Branhamella catarrhalis W-0500	12.5	3.13	1.56	0.78	0.39	0.39	0.78	0.39	0.78	0.78	0.78	0.20
B. catarrhalis W-0506	25	12.5	3.13	1.56	0.78	0.39	0.78	0.78	0.78	0.78	1.56	0.20
Haemophilus influenzae 9334	50	50	6.25	3.13	3.13	1.56	3.13	6.25	6.25	3.13	1.56	1.56


LM-V having a diol structure in the neutral sugar. The compound $(3d \sim 3g)$ were more effective than natural LM-A₇. Compound (3f) having 3-methylbutyl side chain showed the most potent activity *in vitro* which was comparable to that of RKM (Table 1). These new compounds having 3-OH were about two times more active *in vitro* than corresponding to 3-O-propionyl analogues.

Introducing other alkyl group in place of methyl into the 3"-OH position slightly reduced the activity. Although mycarose analogue, compound (22), showed excellent antibacterial activities, its chemical stability was obviously lower than those of cladinose analogues under acidic conditions (data not shown). Thus, introducing a methyl group onto the 3"-OH position increased a stability of the glycosyl bond of the neutral sugar, probably because of a 1,3-diaxial steric factor.

The most potent analogue, **3f**, was incubated in rat plasma to clarify its metabolic stability against esterase. Fig. 4 shows changes in the relative antibacterial activities against *Micrococcus luteus*, expressed by referring the initial activity of each compound in the plasma to 100%. The metabolic stability of **3f** was relatively improved compared with a structurally related 4-O-acyl- α -L-mycarosyl compound, LM-A₇ or 3,4-di-O-acyl- α -L-mycarosyl compound, RKM, since the neutral sugar moiety of **3f** could not be attacked by esterase. It must also be pointed out that the half-life (T_{1/2}) of **3f** was 3~4 times longer than those of RKM and LM-A₇. Thus, a greater stability has been achieved *in vitro* by introducing 4-O-alkyl-L-cladinose instead of 4-O-acyl-L-mycarose in sixteen-membered macrolides.

Preliminary pharmacokinetics of 3f were examined with three antibiotics in mice. Serum concentrations

Fig. 4. Time course of relative potency. Rat plasma (t=0; 100%, 37°C), \bigcirc 3f, \bullet RKM, \bullet LM-A₇.



after 200 mg/kg oral administration are shown in Fig. 5. A time course pattern of 3f was very close to that of RKM, however, absolute concentrations of 3f were clearly higher than that of RKM. A serum level of LM-A7 was less than RKM, undoubtedly (data not shown). The maximum concentration of 3f in serum was comparable to that of clarithromycin (CAM)¹⁷⁾ despite the free C-3 hydroxyl group of compound (3f). These excellent results led us to clarify further pharmacokinetic study of 3f using hamsters as rather large test animals. In the field of sixteen-membered macrolides, pharmacokinetics are sometimes strongly affected with animal species⁷⁾. Fig. 6 shows concentrations of antibiotics in serum of hamsters after 500 mg/kg oral administration. The maximum concentration of 3f is higher than that of RKM or CAM.

Extremely high efficacy of synthesized **3f** *in vivo* may be promising with both its potent antibacterial activities *in vitro* and its splendidly high serum concentrations *in vivo*. The described chemistry is efficient considering the

Fig. 5. Concentration in serum.

200 mg/kg, mouse, n=2, p.o., ○ 3f, ● RKM, ■ CAM.





Fig. 6. Concentration in serum.500 mg/kg, hamster, n = 1, p.o., ○ 3f, ● RKM, ■ CAM.



complexity of the designed molecules, and opens the way for eventually new chemical modifications of naturally occurring sixteen-membered macrolides. In addition, discovery of a quite potent analogue (3f) might allow the sixteen-membered macrolide antibiotics to exhibit closer efficacy to the second generation fourteen-membered macrolides, so-called *new* macrolides such as CAM.

Experimental

General Methods

MP's were determined with a Yanagimoto micro melting point apparatus and were uncorrected. Optical rotations were measured on a Perkin-Elmer 241 polarimeter. Mass spectra were obtained on a Hitachi M-80A or M-80B mass spectrometer for EI-MS or FD-, SI-MS, respectively. ¹H NMR spectra were measured with a Jeol JNM-GSX 400 NMR spectrometer for 400 MHz in CDCl₃ using TMS as internal standard. Silica gel chromatography and preparative TLC were performed on Merck Kieselgel 60 and Merck TLC 60F₂₅₄, respectively. In general, organic layer was dried with anhydrous Na₂SO₄, evaporation and concentration were carried out under reduced pressure below 30°C, unless otherwise noted.

Antibacterial Activity In Vitro

Minimum inhibitory concentration (MIC) was determined by the agar plate dilution method. Test strains were subjected to seed culture using Sensitivity test broth (STB, Nissui Pharmaceutical) except that the strains belonging to the genus *Streptococcus*, *Branhamella* and *Haemophilus* were cultured on blood agar plate. A $5\,\mu$ l portion of cell suspension of the test strains having about $10^6\,\mathrm{CFU/ml}$ was inoculated into Sensitivity disk agar (SDA, Nissui Pharmaceutical) supplemented with 5% horse blood and incubated at $37^\circ\mathrm{C}$ for 20 hours. Then, MIC was measured.

Metabolic Stability in Rat Plasma In Vitro

A solution of each test compound (500 μ g) in CH₃OH (50 μ l) were added to thawed rat plasma (950 μ l) and the mixture was incubated at 37°C. A 20 μ l portion of the mixture was sampled after 0, 0.5, 1, 2, and 4 hours and added to 0.05 M phosphate buffer (pH 7.6, 980 μ l) including small amount of DFP. A 20 μ l portion of the sample solution was used to measure antibacterial activity against *M. luteus* ATCC9341. The starting activity of each compound in rat plasma was reffered to as 100%.

Pharmacokinetics (Serum Level) Tests in Mice In Vivo

A test compound was mixed with a 0.2% aqueous solution of CMC to give a concentration of 4.0 mg/ml and a 1.0 ml portion of the resulting emulsion was orally

administrated to 4 weeks old male Jcl: ICR mice. Blood was collected from armpit of the mice 0.5, 1, 2, 4 and 6 hours after the administration of the test compound (n=2). The collected blood was allowed to stand at 0°C for 2 hours and centrifuged at 3000 rpm for 20 minutes to obtain serum. To the serum was added an equivalent volume of 50% CH₃CN-0.05 m phosphate buffer (pH 7.0). The resulting mixture served as a serum sample. The concentration of the test compound in the serum sample was measured by a bioassay method using *M. luteus* ATCC9341.

Pharmacokinetics (Serum Level) Tests in Hamsters In Vivo

A test compound was mixed with a 0.2% aqueous solution of CMC to give a concentration of 40 mg/ml and a 1.0 ml portion of the resulting emulsion was orally administrated to 5 weeks old female Std: Syrian hamsters (ca. 80 g body weight). Blood was collected from armpit of the hamsters 0.5, 1, 2 and 4 hours after the administration of the test compound (n=1). The collected blood was allowed to stand at 0°C for 2 hours and centrifuged at 3000 rpm for 20 minutes to obtain serum. To the serum was added an equivalent volume of 50% CH₃CN-0.05 M phosphate buffer (pH 7.0). The resulting mixture served as a serum sample. The concentration of the test compound in the serum sample was measured by a bioassay method using M. luteus ATCC9341.

9,18,2'-Tri-*O-tert*-butyldimethylsilylleucomycin A₇ 3,18-Acetal (4)

To 1.00 g (1.32 mmol) of leucomycin A₇ was added dry DMF (12 ml), and 1.18 g (7.82 mmol) of t-butyl-dimethylsilyl chloride and 1.08 g (15.8 mmol) of imidazole were added. The mixture was stirred at 50°C for 24 hours. The reaction mixture was cooled to room temperature, and CH₃OH (50 ml) was added followed by stirring at room temperature for 30 minutes. Evaporation gave a residue which was extracted with benzene (500 ml) and the benzene layer was successively washed with saturated aqueous NaHCO₃ (500 ml) twice and brine (500 ml) twice. Then the organic layer was dried and concentrated to afford 1.22 g of crude 4. A 60 mg portion of this crude compound was purified by preparative TLC [CHCl₃-MeOH (50:1)] to give 35 mg (83%) of 4.

MP $105 \sim 107^{\circ}$ C; $[\alpha]_{D} - 17^{\circ}$ (c 1.0, CH₃OH); SI-MS m/z 1100 (M+H)⁺; ¹H NMR δ 0.41 (1H, br dd, 7-H), 1.11 (3H, s, 3"-CH₃), 1.17 (3H, t, 4"-OCOCH₂CH₃), 1.25 (3H, d, 6'-H), 1.30 (3H, d, 16-H), 1.38 (1H, dt, 17-H), 1.66 (1H, br d, 17-H), 1.86 (1H, dd, 2"-Hax), 2.00 (1H, d, 2"-Heq), 2.53 (6H, s, 3'-N(CH₃)₂), 2.55 (1H, t, 3'-H), 2.61 (1H, dd, 2-H), 3.14 (1H, br s, 4-H), 3.35 (1H, t, 4'-H), 3.38 (3H, s, 4-OCH₃), 3.42 (1H, br dd, 5-H), 3.52 (1H, dd, 2'-H), 4.21 (1H, d, 1'-H), 4.22 (1H, m, 3-H), 4.23 (1H, m, 9-H), 4.37 (1H, dq, 5"-H), 4.62 (1H, d, 4"-H), 4.63 (1H, br dd, 18-H), 4.85 (1H, ddq,

15-H), 5.10 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.75 (1H, dd, 10-H), 6.12 (1H, m, 11-H), 6.12 (1H, m, 12-H).

9,18,2'-Tri-*O-tert*-butyldimethylsilylleucomycin V 3,18-Acetal (5)

One hundred thirty ml of benzene was added to 1.16 g (1.05 mmol) of crude 4, and 25% aqueous NaOH (65 ml) and 358 mg (1.05 mmol) of tetra-n-butylammonium hydrogensulfate were added. After vigorous stirring at room temperature for 2 hours, the benzene layer was collected and washed with brine (150 ml) twice. The organic layer was dried and concentrated. The residue thus obtained was purified by silica gel column chromatography [200 g, CHCl₃-MeOH (30:1)] to give 795 mg (0.76 mmol, 72% overall 2 steps) of 5.

MP 98 ~ 100°C; $[\alpha]_D$ — 12° (c 1.0, CH₃OH); SI-MS m/z 1044 (M+H)⁺; ¹H NMR δ 0.41 (1H, br dd, 7-H), 1.22 (3H, s, 3"-CH₃), 1.25 (3H, d, 6'-H), 1.30 (3H, d, 6"-H), 1.30 (3H, d, 16-H), 1.38 (1H, dt, 17-H), 1.66 (1H, br d, 17-H), 1.77 (1H, dd, 2"-Hax), 2.02 (1H, d, 2"-Heq), 2.37 (1H, br dd, 2-H), 2.51 (6H, s, 3'-N(CH₃)₂), 2.53 (1H, t, 3'-H), 2.61 (1H, dd, 2-H), 2.94 (1H, t, 4"-H), 3.13 (1H, br s, 4-H), 3.32 (1H, t, 4'-H), 3.37 (3H, s, 4-OCH₃), 3.42 (1H, br dd, 5-H), 3.57 (1H, dd, 2'-H), 3.99 (1H, dq, 5"-H), 4.20 (1H, d, 1'-H), 4.21 (1H, m, 3-H), 4.23 (1H, m, 9-H), 4.63 (1H, br dd, 18-H), 4.85 (1H, ddq, 15-H), 5.08 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.74 (1H, dd, 10-H), 6.11 (1H, m, 11-H), 6.11 (1H, m, 12-H).

9,18,2'-Tri-*O-tert*-butyldimethylsilyl-4"-*O*-(3-methylbutyl)leucomycin V 3,18-Acetal (**6f**)

To a stirred mixture of **5** (1.00 g, 0.95 mmol) and oily sodium hydride (192 mg as 60%, 4.8 mmol) in dry DMF (15 ml) was added 1-iodo-3-methylbutane (5.70 g, 28.8 mmol). The resulting mixture was stirred at 45°C for 1 hour, and it was cooled to room temperature. After slowly adding H₂O (250 ml), the reaction mixture was extracted with CHCl₃ (250 ml) twice. The organic layers were combined, washed with brine (500 ml) twice and dried. Evaporation gave a residue which was purified by silica gel column chromatography [150 g, hexane-EtOAc (2:1)]. Thus, 715 mg (0.64 mmol, 68%) of **6f** was obtained.

MP $84 \sim 86^{\circ}$ C; $[\alpha]_D - 13^{\circ}$ (c 1.0, CH₃OH); SI-MS m/z 1113 (M)⁺; ¹H NMR δ 0.38 (1H, br dd, 7-H), 1.23 (3H, s, 3"-CH₃), 1.38 (1H, dt, 17-H), 1.49 (2H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.62 (1H, br d, 17-H), 1.68 (1H, m, 4"-OCH₂ CH₂CH(CH₃)₂), 1.74 (1H, dd, 2"-Hax), 1.95 (1H, br d, 2"-Heq), 2.37 (1H, br dd, 2-H), 2.50 (6H, s, 3'-N(CH₃)₂), 2.52 (1H, t, 3'-H), 2.59 (1H, dd, 2-H), 2.69 (1H, d, 4"-H), 3.34 (1H, t, 4'-H), 3.36 (3H, s, 4-OCH₃), 3.38 (1H, br dd, 5-H), 3.42 (1H, dd, 2'-H), 3.59 and 3.63 (each 1H, dt, 4"-OCH₂CH₂CH(CH₃)₂), 4.16 (1H, d, 1'-H), 4.20 (1H, m, 3-H), 4.20 (1H, m, 9-H), 4.20 (1H, dq, 5"-H), 4.60 (1H, br dd, 18-H), 4.81 (1H, ddq, 15-H), 5.01 (1H, d, 1"-H), 5.60 (1H, dt, 13-H), 5.73 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

9,18,2'-Tri-*O-tert*-butyldimethylsilyl-4"-*O*-ethylleucomycin V 3,18-Acetal (**6b**)

Reaction of 5 with iodoethane gave 6b in 68% yield by a similar procedure to 6f.

MP 92°C; [α]_D -17° (c 1.0, CH₃OH); SI-MS m/z 1072 (M+H)⁺; ¹H NMR δ 0.39 (1H, br dd, 7-H), 1.23 (3H, s, 3"-CH₃), 1.38 (1H, dt, 17-H), 1.63 (1H, br d, 17-H), 1.75 (1H, dd, 2"-Hax), 1.96 (1H, br d, 2"-Heq), 2.37 (1H, br dd, 2-H), 2.50 (6H, s, 3'-N(CH₃)₂), 2.52 (1H, t, 3'-H), 2.60 (1H, dd, 2-H), 2.70 (1H, d, 4"-H), 3.34 (1H, t, 4'-H), 3.37 (3H, s, 4-OCH₃), 3.38 (1H, br dd, 5-H), 3.44 (1H, dd, 2'-H), 3.66 and 3.68 (each 1H, dq, 4"-OCH₂CH₃), 4.16 (1H, d, 1'-H), 4.21 (1H, m, 3-H), 4.21 (1H, m, 9-H), 4.22 (1H, dq, 5"-H), 4.61 (1H, br dd, 18-H), 4.82 (1H, ddq, 15-H), 5.02 (1H, d, 1"-H), 5.60 (1H, dt, 13-H), 5.73 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

9,18,2'-Tri-*O-tert*-butyldimethylsilyl-4"-*O-n*-propylleucomycin V 3,18-Acetal (**6c**)

Reaction of 5 with 1-iodopropane gave 6c in 90% yield by a similar procedure to 6f.

MP 88~90°C; $[\alpha]_D$ –11° (c 1.0, CH₃OH); FD-MS m/z 1085 (M)⁺; ¹H NMR δ 0.39 (1H, br dd, 7-H), 0.92 (3H, t, 4"-OCH₂CH₂CH₃), 1.25 (3H, s, 3"-CH₃), 1.39 (1H, dt, 17-H), 1.76 (1H, dd, 2"-Hax), 1.97 (1H, br d, 2"-Heq), 2.38 (1H, br dd, 2-H), 2.51 (6H, s, 3'-N(CH₃)₂), 2.53 (1H, t, 3'-H), 2.60 (1H, dd, 2-H), 2.71 (1H, d, 4"-H), 3.35 (1H, t, 4'-H), 3.37 (3H, s, 4-OCH₃), 3.39 (1H, br dd, 5-H), 3.43 (1H, dd, 2'-H), 3.56 (2H, t, 4"-OCH₂CH₂CH₃), 4.17 (1H, d, 1'-H), 4.22 (1H, m, 3-H), 4.22 (1H, m, 9-H), 4.23 (1H, dq, 5"-H), 4.62 (1H, br dd, 18-H), 4.82 (1H, ddq, 15-H), 5.03 (1H, d, 1"-H), 5.61 (1H, dt, 13-H), 5.75 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

4"-O-n-Butyl-9,18,2'-tri-O-tert-butyldimethylsilyl-leucomycin V 3,18-Acetal (6d)

Reaction of 5 with 1-bromobutane gave 6d in 67% yield by a similar procedure to 6f.

MP 82~83°C; $[\alpha]_D$ – 13° (c 1.0, CH₃OH); FD-MS m/z 1099 (M)⁺; ¹H NMR δ 0.40 (1H, br dd, 7-H), 0.90 (3H, t, 4"-OCH₂CH₂CH₂CH₂CH₃), 1.24 (3H, s, 3"-CH₃), 1.39 (1H, dt, 17-H), 1.64 (1H, br d, 17-H), 1.75 (1H, dd, 2"-Hax), 1.97 (1H, br d, 2"-Heq), 2.38 (1H, br dd, 2-H), 2.51 (6H, s, 3'-N(CH₃)₂), 2.53 (1H, t, 3'-H), 2.60 (1H, dd, 2-H), 2.70 (1H, d, 4"-H), 3.34 (1H, t, 4'-H), 3.37 (3H, s, 4-OCH₃), 3.39 (1H, br dd, 5-H), 3.43 (1H, dd, 2'-H), 3.60 (2H, dt, 4"-OCH₂CH₂CH₂CH₃), 4.17 (1H, d, 1'-H), 4.22 (1H, m, 3-H), 4.22 (1H, m, 9-H), 4.22 (1H, dq, 5"-H), 4.62 (1H, br dd, 18-H), 4.82 (1H, ddq, 15-H), 5.03 (1H, d, 1"-H), 5.61 (1H, dt, 13-H), 5.74 (1H, dd, 10-H), 6.11 (1H, m, 11-H), 6.11 (1H, m, 12-H).

9,18,2'-Tri-*O-tert*-butyldimethylsilyl-4"-*O-n*-pentyl-leucomycin V 3,18-Acetal (**6e**)

Reaction of 5 with 1-iodopentane gave 6e in 77% yield by a similar procedure to 6f.

MP $77 \sim 78^{\circ}$ C; $[\alpha]_{D} - 13^{\circ}$ (c 1.0, CH₃OH); FD-MS

m/z 1113 (M)⁺; ¹H NMR δ 0.40 (1H, br dd, 7-H), 1.24 (3H, s, 3"-CH₃), 1.39 (1H, dt, 17-H), 1.76 (1H, dd, 2"-Hax), 1.97 (1H, br d, 2"-Heq), 2.38 (1H, br dd, 2-H), 2.51 (6H, s, 3'-N(CH₃)₂), 2.53 (1H, t, 3'-H), 2.61 (1H, dd, 2-H), 2.70 (1H, d, 4"-H), 3.35 (1H, t, 4'-H), 3.37 (3H, s, 4-OCH₃), 3.39 (1H, br dd, 5-H), 3.43 (1H, dd, 2'-H), 3.59 (2H, dt, 4"-OCH₂CH₂CH₂CH₂CH₃), 4.17 (1H, d, 1'-H), 4.22 (1H, m, 3-H), 4.22 (1H, m, 9-H), 4.22 (1H, dq, 5"-H), 4.62 (1H, br dd, 18-H), 4.83 (1H, ddq, 15-H), 5.03 (1H, d, 1"-H), 5.61 (1H, dt, 13-H), 5.74 (1H, dd, 10-H), 6.11 (1H, m, 11-H), 6.11 (1H, m, 12-H).

4"-O-Benzyl-9,18,2'-tri-O-tert-butyldimethylsilyl-leucomycin V 3,18-Acetal (**6g**)

Reaction of 5 with benzyl bromide gave 6g in 90% yield by a similar procedure to 6f.

FD-MS m/z 1133 (M)⁺; ¹H NMR δ 0.42 (1H, br dd, 7-H), 1.23 (3H, s, 3"-CH₃), 1.32 (3H, d, 16-H), 1.41 (1H, dt, 17-H), 1.66 (1H, br d, 17-H), 1.79 (1H, dd, 2"-Hax), 1.99 (1H, br d, 2"-Heq), 2.40 (1H, br dd, 2-H), 2.54 (6H, s, 3'-N(CH₃)₂), 2.56 (1H, t, 3'-H), 2.63 (1H, dd, 2-H), 2.95 (1H, d, 4"-H), 3.33 (1H, dq, 5'-H), 3.38 (1H, t, 4'-H), 3.40 (3H, s, 4-OCH₃), 3.42 (1H, br dd, 5-H), 3.48 (1H, dd, 2'-H), 4.20 (1H, d, 1'-H), 4.23 (1H, m, 3-H), 4.24 (1H, m, 9-H), 4.33 (1H, dq, 5"-H), 4.64 (1H, br dd, 18-H), 4.71 (2H, dd, 4"-OCH₂C₆H₅), 4.85 (1H, ddq, 15-H), 5.06 (1H, d, 1"-H), 5.64 (1H, dt, 13-H), 5.77 (1H, dd, 10-H), 6.13 (1H, m, 11-H), 6.13 (1H, m, 12-H).

9,18-Di-*O-tert*-butyldimethylsilyl-3"-*O*-methyl-4"-*O*-(3-methylbutyl)leucomycin V 3,18-Acetal (9f)

To a solution of **6f** (1.42 g, 1.27 mmol) in CHCl₃ (71 ml) was added mCPBA (328 mg, 1.90 mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous $Na_2S_2O_3$ (150 ml) and extracted with CHCl₃ (500 ml). The organic layer was successively washed with saturated aqueous NaHCO₃ (500 ml) twice and brine (500 ml) twice. Then, the organic layer was dried and concentrated to afford 1.42 g of N-oxide (7f). To a stirred mixture of crude 7f (1.42g) and oily sodium hydride (251 mg as 60%, 6.27 mmol) in dry DMF (14 ml) was added iodomethane (5.39 g, 37.9 mmol). The resulting mixture was stirred at 45°C for 1 hour, then cooled to room temperature. After slowly adding H₂O (500 ml), the mixture was extracted with CHCl₃ (500 ml) twice. The organic layers were combined and washed with brine (500 ml) twice, dried and concentrated to give 1.55 g of crude 8f. A 190 mg portion of this oily product was dissolved in MeOH (12 ml) and adsorbed by 16.0 g of silica gel (Merck Kieselgel 60). After distilling off MeOH under reduced pressure, the residue was allowed to stand overnight. Then, the substance adsorbed by the silica gel was extracted with a mixture [CHCl₃-MeOH (5:1)]. The extract was purified by silica gel column chromatography [12 g, CHCl₃-MeOH (50:1)] to afford 103 mg (65% overall 3 steps) of 9f.

MP $68 \sim 70^{\circ}$ C; $[\alpha]_{D} - 2^{\circ}$ (c 1.0, CH₃OH); SI-MS m/z

1014 (M+H)⁺; ¹H NMR δ 0.42 (1H, br dd, 7-H), 1.22 (3H, s, 3"-CH₃), 1.31 (3H, d, 16-H), 1.43 (1H, dt, 17-H), 1.54 (1H, dd, 2"-Hax), 1.66 (1H, br d, 17-H), 2.21 (1H, d, 2"-Heq), 2.42 (1H, dd, 2-H), 2.46 (1H, t, 3'-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.76 (1H, d, 4"-H), 3.25 (3H, s, 3"-OCH₃), 3.32 (1H, dd, 2'-H), 3.36 (1H, t, 4'-H), 3.44 (3H, s, 4-OCH₃), 3.46 (1H, dd, 5-H), 3.57 and 3.63 (each 1H, dt, 4"-OCH₂CH₂CH(CH₃)₂), 4.05 (1H, br dt, 3-H), 4.18 (1H, br d, 9-H), 4.30 (1H, d, 1'-H), 4.45 (1H, dq, 5"-H), 4.57 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.87 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.73 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

9,18-Di-*O-tert*-butyldimethylsilyl-4"-*O*-ethyl-3"-*O*-methylleucomycin V 3,18-Acetal (**9b**)

Reactions of **6b** gave **9b** via **7b** and **8b** in 63% yield (overall 3 steps) by similar procedures to **9f**.

MP 72 ~ 74°C; [α]_D -2° (c 1.0, CH₃OH); SI-MS m/z 971 (M)⁺; ¹H NMR δ 0.41 (1H, br dd, 7-H), 1.21 (3H, s, 3"-CH₃), 1.30 (3H, d, 16-H), 1.43 (1H, dt, 17-H), 1.52 (1H, dd, 2"-Hax), 1.66 (1H, br d, 17-H), 2.23 (1H, d, 2"-Heq), 2.45 (1H, t, 3'-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.76 (1H, d, 4"-H), 3.25 (3H, s, 3"-OCH₃), 3.32 (1H, dd, 2'-H), 3.36 (1H, t, 4'-H), 3.43 (3H, s, 4-OCH₃), 3.45 (1H, br d, 5-H), 3.64 and 3.68 (each 1H, dq, 4"-OCH₂CH₃), 4.05 (1H, br dt, 3-H), 4.18 (1H, br d, 9-H), 4.29 (1H, d, 1'-H), 4.45 (1H, dq, 5"-H), 4.56 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.87 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.72 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

9,18-Di-*O-tert*-butyldimethylsilyl-3"-*O*-methyl-4"-*On*-propylleucomycin V 3,18-Acetal (**9c**)

Reactions of **6c** gave **9c** via **7c** and **8c** in 64% yield (overall 3 steps) by similar procedures to **9f**.

MP 67 ~ 69°C; $[\alpha]_D$ — 3° (c 1.0, CH₃OH); SI-MS m/z 986 (M+H)⁺; ¹H NMR δ 0.42 (1H, br dd, 7-H), 1.23 (3H, s, 3"-CH₃), 1.31 (3H, d, 16-H), 1.43 (1H, dt, 17-H), 1.54 (1H, dd, 2"-Hax), 1.63 (2H, m, 4"-OCH₂CH₂CH₃), 1.65 (1H, br d, 17-H), 2.22 (1H, d, 2"-Heq), 2.47 (1H, t, 3'-H), 2.56 (6H, s, 3'-N(CH₃)₂), 2.77 (1H, d, 4"-H), 3.25 (3H, s, 3"-OCH₃), 3.32 (1H, dd, 2'-H), 3.36 (1H, t, 4'-H), 3.43 (3H, s, 4-OCH₃), 3.54 and 3.57 (each 1H, dt, 4"-OCH₂CH₂CH₃), 4.05 (1H, br dt, 3-H), 4.18 (1H, br dt, 9-H), 4.30 (1H, d, 1'-H), 4.45 (1H, dq, 5"-H), 4.57 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.87 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.73 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

4"-O-n-Butyl-9,18-di-O-tert-butyldimethylsilyl-3"-O-methylleucomycin V 3,18-Acetal (9d)

Reactions of **6d** gave **9d** via **7d** and **8d** in 63% yield (overall 3 steps) by similar procedures to **9f**.

MP 67~68°C; $[\alpha]_D$ -4° (c 1.0, CH₃OH); SI-MS m/z 999 (M+H)⁺; ¹H NMR δ 0.42 (1H, br dd, 7-H), 0.99 (3H, t, 4″-OCH₂CH₂CH₂CH₃), 1.22 (3H, s, 3″-CH₃), 1.30 (3H, d, 16-H), 1.36 (2H, m, 4″-OCH₂CH₂CH₂CH₃), 1.43 (1H, dt, 17-H), 1.53 (1H, dd, 2″-Hax), 1.58 (2H, m,

4"-OCH₂CH₂CH₂CH₃), 1.66 (1H, br d, 17-H), 2.21 (1H, d, 2"-Heq), 2.46 (1H, t, 3'-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.76 (1H, d, 4"-H), 3.25 (3H, s, 3"-OCH₃), 3.32 (1H, dd, 2'-H), 3.36 (1H, t, 4'-H), 3.44 (3H, s, 4-OCH₃), 3.46 (1H, dd, 5-H), 3.57 and 3.61 (each 1H, dt, 4"-OCH₂CH₂CH₂CH₃), 4.05 (1H, br dt, 3-H), 4.18 (1H, br d, 9-H), 4.29 (1H, d, 1'-H), 4.45 (1H, dq, 5"-H), 4.56 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.87 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.73 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

9,18-Di-*O-tert*-butyldimethylsilyl-3"-*O*-methyl-4"-*O*-n-pentylleucomycin V 3,18-Acetal (**9e**)

Reactions of **6e** gave **9e** via **7e** and **8e** in 64% yield (overall 3 steps) by similar procedures to **9f**.

MP 63 ~ 64°C; $[\alpha]_D$ — 2° (c 1.0, CH₃OH); SI-MS m/z 1014 (M+H)⁺; ¹H NMR δ 0.42 (1H, br dd, 7-H), 1.22 (3H, s, 3"-CH₃), 1.31 (3H, d, 16-H), 1.43 (1H, dt, 17-H), 1.54 (1H, dd, 2"-Hax), 1.66 (1H, br d, 17-H), 2.22 (1H, d, 2"-Heq), 2.47 (1H, t, 3'-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.76 (1H, d, 4"-H), 3.25 (3H, s, 3"-OCH₃), 3.32 (1H, dd, 2'-H), 3.36 (1H, t, 4'-H), 3.44 (3H, s, 4-OCH₃), 3.45 (1H, dd, 5-H), 3.54 and 3.60 (each 1H, dt, 4"-OCH₂CH₂CH₂CH₂CH₃), 4.06 (1H, br dt, 3-H), 4.18 (1H, br d, 9-H), 4.29 (1H, d, 1'-H), 4.45 (1H, dq, 5"-H), 4.57 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.87 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.73 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

4"-O-Benzyl-9,18-di-O-tert-butyldimethylsilyl-3"-O-methylleucomycin V 3,18-Acetal (9g)

Reactions of **6g** gave **9g** via **7g** and **8g** in 51% yield (overall 3 steps) by similar procedures to **9f**.

MP 61 ~ 63°C; [α]_D - 2° (c 1.0, CH₃OH); FD-MS m/z 1033 (M)⁺; ¹H NMR δ 0.44 (1H, br dd, 7-H), 1.24 (3H, s, 3"-CH₃), 1.33 (3H, d, 16-H), 1.45 (1H, dt, 17-H), 1.56 (1H, dd, 2"-Hax), 1.68 (1H, br d, 17-H), 2.22 (1H, d, 2"-Heq), 2.57 (6H, s, 3'-N(CH₃)₂), 3.00 (1H, d, 4"-H), 3.27 (3H, s, 3"-OCH₃), 3.35 (1H, dd, 2'-H), 3.38 (1H, t, 4'-H), 3.46 (3H, s, 4-OCH₃), 3.48 (1H, dd, 5-H), 4.08 (1H, br dt, 3-H), 4.21 (1H, br d, 9-H), 4.32 (1H, d, 1'-H), 4.54 (1H, dq, 5"-H), 4.59 (1H, br dd, 18-H), 4.67 (2H, dd, 4"-OCH₂C₆H₅), 4.82 (1H, ddq, 15-H), 4.90 (1H, d, 1"-H), 5.64 (1H, dt, 13-H), 5.74 (1H, dd, 10-H), 6.12 (1H, m, 11-H), 6.12 (1H, m, 12-H), 7.3 ~ 7.4 (5H, m, 4"-OCH₂C₆H₅).

9,18-Di-*O-tert*-butyldimethylsilyl-3",4"-di-*O*-methyl-leucomycin V 3,18-Acetal (**9a**)

To a solution of 5 (200 mg, 0.19 mmol) in CHCl₃ (10 ml) was added mCPBA (50 mg, 0.28 mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous Na₂S₂O₃ (100 ml) and extracted with CHCl₃ (100 ml). The organic layer was successively washed with saturated aqueous NaHCO₃ (100 ml) twice and brine (100 ml) twice. Then, the organic layer was dried and concentrated to afford 200 mg of N-oxide of 5. To a stirred mixture of this crude N-

oxide (200 mg) and oily sodium hydride (60 mg as 60%, 1.5 mmol) in dry DMF (2.0 ml) was added iodomethane (1.2 g, 8.4 mmol). The resulting mixture was stirred at 45°C for 1 hour, then cooled to room temperature. After slowly adding H₂O (100 ml), the mixture was extracted with CHCl₃ (100 ml) twice. The organic layers were combined and washed with brine (100 ml) twice, dried and concentrated to give 170 mg of crude 8a. This oily product was charged on preparative TLC plates (Merck TLC 60F₂₅₄). After allowing the plates stand for 2 days, and then development was carried out for purification [CHCl₃-MeOH (20:1)] to afford 93 mg (0.10 mmol, 51% overall 3 steps) of 9a.

MP 76°C; $[\alpha]_D - 4^\circ$ (c 1.0, CH₃OH); FD-MS m/z 958 (M+H)⁺; ¹H NMR δ 0.41 (1H, br dd, 7-H), 1.23 (3H, s, 3"-CH₃), 1.30 (3H, d, 16-H), 1.43 (1H, dt, 17-H), 1.52 (1H, dd, 2"-Hax), 1.66 (1H, br d, 17-H), 2.22 (1H, d, 2"-Heq), 2.46 (1H, t, 3'-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.66 (1H, d, 4"-H), 3.24 (3H, s, 3"-OCH₃), 3.33 (1H, dd, 2'-H), 3.36 (1H, t, 4'-H), 3.44 (3H, s, 4-OCH₃), 3.46 (1H, br d, 5-H), 3.53 (3H, s, 4"-OCH₃), 4.05 (1H, br dt, 3-H), 4.18 (1H, br d, 9-H), 4.30 (1H, d, 1'-H), 4.44 (1H, dq, 5"-H), 4.57 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.87 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.72 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

2'-O-Acetyl-9,18-di-*O-tert*-butyldimethylsilyl-3"-*O*-methyl-4"-*O*-(3-methylbutyl)leucomycin V 3,18-Acetal (10)

To a stirred solution of 9f (30 mg, 0.03 mmol) in dry CH_3CN (0.90 ml) was added at room temperature acetic anhydride (6.0 μ l, 0.06 mmol). After stirring at 30°C for 16 hours, 1.0 m NH_4OH (0.90 ml, 0.09 mmol) was added to the resulting solution, which was allowed to stand at room temperature for 20 minutes. Evaporation gave a residue which was extracted with $CHCl_3$ (30 ml) and the organic layer was washed with saturated aqueous $NaHCO_3$ (30 ml) and brine (30 ml). This was concentrated and purified by preparative TLC [hexane - acetone (2:1)] to afford 29 mg (92%) of 10.

MP $66 \sim 71^{\circ}\text{C}$; $[\alpha]_D - 15^{\circ}$ (c 1.0, CH₃OH); EI-MS m/z 1055 (M)⁺; ¹H NMR δ 0.42 (1H, brdd, 7-H), 1.23 (3H, s, 3"-CH₃), 1.30 (3H, d, 16-H), 2.10 (3H, s, 2'-OCOCH₃), 2.22 (1H, d, 2"-Heq), 2.43 (6H, s, 3'-N(CH₃)₂), 2.75 (1H, d, 4"-H), 3.17 (1H, t, 4'-H), 3.28 (3H, s, 3"-OCH₃), 3.42 (3H, s, 4-OCH₃), 3.62 (2H, m, 4"-OCH₂CH₂CH(CH₃)₂), 4.14 (1H, brdd, 3-H), 4.19 (1H, brdd, 9-H), 4.27 (1H, d, 1'-H), 4.45 (1H, dq, 5"-H), 4.54 (1H, brdd, 18-H), 4.64 (1H, ddq, 15-H), 4.80 (1H, d, 1"-H), 5.06 (1H, dd, 2'-H), 5.47 (1H, dt, 13-H), 5.96 (1H, m, 10-H), 5.96 (1H, m, 11-H), 6.32 (1H, dd, 12-H).

3"-O-Methyl-4"-O-(3-methylbutyl)leucomycin V (3f) To 1.07 g (1.05 mmol) of 9f was added 8.4 ml of a 2.0 M solution of TBAF in THF and the mixture was allowed to react at 45°C for 1 hour. Then the reaction mixture was dropped into 5% aqueous KHSO₄ (50 ml) and then extracted with CHCl₃ (300 ml) twice. The organic layers

were combined and successively washed with saturated aqueous NaHCO₃ (600 ml) twice and brine (600 ml) twice. The organic layer was dried, concentrated and the resulting residue was purified by silica gel column chromatography [100 g, CHCl₃-MeOH (50:1)]. Thus, 565 mg (0.72 mmol, 69%) of 3f was obtained.

MP $87 \sim 91^{\circ}$ C; $[\alpha]_{D} - 64^{\circ}$ (c 0.8, CH₃OH); EI-MS m/z 785 (M)⁺; ¹H NMR δ 0.89 (6H, d, 4"-OCH₂CH₂- $CH(CH_3)_2$), 0.99 (3H, d, 19-H), 1.18 (3H, d, 6'-H), 1.23 (3H, d, 6"-H), 1.25 (3H, s, 3"-CH₃), 1.31 (3H, d, 16-H), 1.52 (2H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.57 (1H, dd, 2"-Hax), 1.70 (1H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.91 (1H, m, 8-H), 2.13 (1H, dt, 14-H), 2.22 (1H, br d, 2-H), 2.23 (1H, d, 2"-Heq), 2.34 (1H, br dd, 17-H), 2.41 (1H, t, 3'-H), 2.52 (1H, br d, 14-H), 2.57 (6H, s, 3'-N(CH₃)₂), 2.71 (1H, dd, 2-H), 2.79 (1H, d, 4"-H), 2.88 (1H, br dd, 17-H), 3.10 (1H, brd, 4-H), 3.18 (1H, dd, 2'-H), 3.26 (3H, s, 3"-OCH₃), 3.28 (1H, dq, 5'-H), 3.48 (1H, t, 4'-H), 3.55 (3H, s, 4-OCH₃), 3.60 and 3.64 (each 1H, dt, 4"-OCH₂CH₂CH(CH₃)₂), 3.80 (1H, brd, 3-H), 4.11 (1H, dd, 9-H), 4.12 (1H, br dd, 5-H), 4.43 (1H, dq, 5"-H), 4.60 (1H, d, 1'-H), 4.90 (1H, d, 1"-H), 5.30 (1H, ddq, 15-H), 5.62 (1H, ddd, 13-H), 5.69 (1H, dd, 10-H), 6.04 (1H, br dd, 12-H), 6.27 (1H, dd, 11-H), 9.81 (1H, br s, 18-H).

3",4"-Di-O-methylleucomycin V (3a)

Reaction of 9a gave 3a in 54% yield by a similar procedure to 3f.

MP 99~101°C; $[\alpha]_D$ -53° (c 1.0, CH₃OH); SI-MS m/z 730 (M+H)⁺; ¹H NMR δ 1.16 (3H, d, 6'-H), 1.21 (3H, d, 6"-H), 1.22 (3H, s, 3"-CH₃), 1.29 (3H, d, 16-H), 1.53 (1H, dd, 2"-Hax), 1.87 (1H, m, 8-H), 2.10 (1H, dt, 14-H), 2.20 (1H, br d, 2-H), 2.22 (1H, d, 2"-Heq), 2.31 (1H, br dd, 17-H), 2.40 (1H, t, 3'-H), 2.49 (1H, br d, 14-H), 2.57 (6H, s, 3'-N(CH₃)₂), 2.66 (1H, d, 4"-H), 2.68 (1H, dd, 2-H), 2.85 (1H, br dd, 17-H), 3.08 (1H, br d, 4-H), 3.22 (3H, s, 3"-OCH₃), 3.24 (1H, dq, 5'-H), 3.46 (1H, t, 4'-H), 3.52 (3H, s, 4-OCH₃), 3.52 (3H, s, 4"-OCH₃), 3.77 (1H, br d, 3-H), 4.08 (1H, dd, 9-H), 4.09 (1H, br dd, 5-H), 4.37 (1H, dq, 5"-H), 4.57 (1H, d, 1'-H), 4.88 (1H, d, 1"-H), 5.27 (1H, ddq, 15-H), 5.59 (1H, ddd, 13-H), 5.66 (1H, dd, 10-H), 6.02 (1H, br dd, 12-H), 6.25 (1H, dd, 11-H), 9.80 (1H, br s, 18-H).

4"-O-Ethyl-3"-O-methylleucomycin V (3b)

Reaction of **9b** gave **3b** in 71% yield by a similar procedure to **3f**.

MP 89 ~ 92°C; $[\alpha]_D - 60^\circ$ (c 1.0, CH₃OH); SI-MS m/z 744 (M+H)⁺; ¹H NMR δ 0.99 (3H, d, 19-H), 1.15 (3H, d, 6'-H), 1.21 (3H, s, 3"-CH₃), 1.21 (3H, d, 6"-H), 1.28 (3H, d, 16-H), 1.53 (1H, dd, 2"-Hax), 1.88 (1H, m, 8-H), 2.10 (1H, dt, 14-H), 2.20 (1H, br d, 2-H), 2.22 (1H, d, 2"-Heq), 2.31 (1H, br dd, 17-H), 2.40 (1H, t, 3'-H), 2.48 (1H, br d, 14-H), 2.57 (6H, s, 3'-N(CH₃)₂), 2.68 (1H, dd, 2-H), 2.76 (1H, d, 4"-H), 2.85 (1H, br dd, 17-H), 3.07 (1H, br d, 4-H), 3.22 (3H, s, 3"-OCH₃), 3.24 (1H, dq, 5'-H), 3.45 (1H, t, 4'-H), 3.52 (3H, s, 4-OCH₃), 3.63 and

3.67 (each 1H, dq, 4''-OC H_2 CH₃), 3.76 (1H, br d, 3-H), 4.07 (1H, dd, 9-H), 4.08 (1H, br dd, 5-H), 4.39 (1H, dq, 5"-H), 4.56 (1H, d, 1'-H), 4.87 (1H, d, 1"-H), 5.26 (1H, ddq, 15-H), 5.58 (1H, ddd, 13-H), 5.66 (1H, dd, 10-H), 6.01 (1H, br dd, 12-H), 6.24 (1H, dd, 11-H), 9.80 (1H, br s, 18-H).

3"-O-Methyl-4"-O-n-propylleucomycin V (3c)

Reaction of 9c gave 3c in 94% yield by a similar procedure to 3f.

MP $79 \sim 81^{\circ}$ C; $[\alpha]_{D} -55^{\circ}$ (c 1.0, CH₃OH); SI-MS m/z 758 (M+H)⁺; ¹H NMR δ 0.90 (3H, t, 4"-OCH₂-CH₂CH₃), 0.99 (3H, d, 19-H), 1.15 (3H, d, 6'-H), 1.21 (3H, d, 6"-H), 1.22 (3H, s, 3"-CH₃), 1.28 (3H, d, 16-H), 1.54 (1H, dd, 2"-Hax), 1.60 (2H, m, 4"-OCH₂CH₂CH₃), 1.88 (1H, m, 8-H), 2.10 (1H, dt, 14-H), 2.20 (1H, brd, 2-H), 2.21 (1H, d, 2"-Heq), 2.31 (1H, br dd, 17-H), 2.39 (1H, t, 3'-H), 2.48 (1H, brd, 14-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.68 (1H, dd, 2-H), 2.76 (1H, d, 4"-H), 2.85 (1H, br dd, 17-H), 3.07 (1H, br d, 4-H), 3.16 (1H, dd, 2'-H), 3.23 (3H, s, 3"-OCH₃), 3.25 (1H, dq, 5'-H), 3.45 (1H, t, 4'-H), 3.52 (3H, s, 4-OCH₃), 3.52 and 3.56 (each 1H, dt, 4"-OCH₂CH₂CH₃), 3.77 (1H, br d, 3-H), 4.07 (1H, dd, 9-H), 4.08 (1H, br dd, 5-H), 4.40 (1H, dq, 5"-H), 4.56 (1H, d, 1'-H), 4.87 (1H, d, 1"-H), 5.26 (1H, ddq, 15-H), 5.58 (1H, ddd, 13-H), 5.66 (1H, dd, 10-H), 6.01 (1H, br dd, 12-H), 6.24 (1H, dd, 11-H), 9.80 (1H, br s, 18-H).

4"-O-n-Butyl-3"-O-methylleucomycin V (3d)

Reaction of **9d** gave **3d** in 72% yield by a similar procedure to **3f**.

MP $80 \sim 84^{\circ}$ C; $[\alpha]_{D} - 54^{\circ}$ (c 1.0, CH₃OH); SI-MS m/z 772 (M+H)⁺; ¹H NMR δ 0.89 (3H, t, 4"-OCH₂-CH₂CH₂CH₃), 1.16 (3H, d, 6'-H), 1.21 (3H, d, 6"-H), 1.22 (3H, s, 3"-CH₃), 1.29 (3H, d, 16-H), 1.36 (2H, m, 4"-OCH₂CH₂CH₂CH₃), 1.54 (1H, dd, 2"-Hax), 1.60 (2H, m, 4"-OCH₂CH₂CH₂CH₃), 1.89 (1H, m, 8-H), 2.10 (1H, dt, 14-H), 2.20 (1H, brd, 2-H), 2.21 (1H, d, 2"-Heq), 2.31 (1H, br dd, 17-H), 2.39 (1H, t, 3'-H), 2.49 (1H, br d, 14-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.68 (1H, dd, 2-H), 2.76 (1H, d, 4"-H), 2.86 (1H, br dd, 17-H), 3.08 (1H, brd, 4-H), 3.16 (1H, dd, 2'-H), 3.23 (3H, s, 3"-OCH₃), 3.25 (1H, dq, 5'-H), 3.45 (1H, t, 4'-H), 3.53 $(3H, s, 4-OCH_3)$, 3.55 and 3.60 (each 1H, dt, 4"-OC H_2 -CH₂CH₂CH₃), 3.77 (1H, br d, 3-H), 4.08 (1H, dd, 9-H), 4.09 (1H, br dd, 5-H), 4.40 (1H, dq, 5"-H), 4.57 (1H, d, 1'-H), 4.87 (1H, d, 1"-H), 5.27 (1H, ddq, 15-H), 5.59 (1H, ddd, 13-H), 5.67 (1H, dd, 10-H), 6.02 (1H, br dd, 12-H), 6.25 (1H, dd, 11-H), 9.80 (1H, br s, 18-H).

3"-O-Methyl-4"-O-n-pentylleucomycin V (3e)

Reaction of 9e gave 3e in 77% yield by a similar procedure to 3f.

MP 76~78°C; $[\alpha]_D$ -55° (c 1.0, CH₃OH); SI-MS m/z 786 (M+H)⁺; ¹H NMR δ 0.87 (3H, brt, 4″-OCH₂CH₂CH₂CH₂CH₃), 0.99 (3H, d, 19-H), 1.15 (3H, d, 6′-H), 1.20 (3H, d, 6″-H), 1.22 (3H, s, 3″-CH₃), 1.28

(3H, d, 16-H), 1.54 (1H, dd, 2"-Hax), 1.88 (1H, m, 8-H), 2.10 (1H, dt, 14-H), 2.19 (1H, br d, 2-H), 2.20 (1H, d, 2"-Heq), 2.31 (1H, br dd, 17-H), 2.40 (1H, t, 3'-H), 2.48 (1H, br d, 14-H), 2.56 (6H, s, 3'-N(CH₃)₂), 2.68 (1H, dd, 2-H), 2.75 (1H, d, 4"-H), 3.07 (1H, br d, 4-H), 3.16 (1H, dd, 2'-H), 3.23 (3H, s, 3"-OCH₃), 3.25 (1H, dq, 5'-H), 3.45 (1H, t, 4'-H), 3.52 (3H, s, 4-OCH₃), 3.54 and 3.58 (each 1H, dt, 4"-OCH₂CH₂CH₂CH₂CH₃), 3.77 (1H, br d, 3-H), 4.07 (1H, dd, 9-H), 4.08 (1H, br dd, 5-H), 4.39 (1H, dq, 5"-H), 4.57 (1H, d, 1'-H), 4.86 (1H, d, 1"-H), 5.27 (1H, ddq, 15-H), 5.58 (1H, ddd, 13-H), 5.66 (1H, dd, 10-H), 6.01 (1H, br dd, 12-H), 6.24 (1H, dd, 11-H), 9.80 (1H, br s, 18-H).

4"-O-Benzyl-3"-O-methylleucomycin V (3g)

Reaction of 9g gave 3g in 68% yield by a similar procedure to 3f.

MP $104 \sim 108^{\circ}$ C; $[\alpha]_D - 67^{\circ}$ (c 1.0, CH₃OH); FD-MS m/z 805 (M)⁺; ¹H NMR δ 0.99 (3H, d, 19-H), 1.14 (3H, s, 3"-CH₃), 1.18 (3H, d, 6'-H), 1.23 (3H, d, 6"-H), 1.30 (3H, d, 16-H), 1.56 (1H, dd, 2"-Hax), 1.60 (1H, br dt, 7-H), 1.90 (1H, m, 8-H), 2.12 (1H, dt, 14-H), 2.22 (1H, br d, 2-H), 2.22 (1H, d, 2"-Heq), 2.33 (1H, br dd, 17-H), 2.43 (1H, t, 3'-H), 2.50 (1H, brd, 14-H), 2.58 (6H, s, 3'-N(CH₃)₂), 2.70 (1H, dd, 2-H), 2.86 (1H, br dd, 17-H), 2.99 (1H, d, 4"-H), 3.09 (1H, brd, 4-H), 3.20 (1H, dd, 2'-H), 3.25 (3H, s, 3"-OCH₃), 3.27 (1H, dq, 5'-H), 3.48 (1H, t, 4'-H), 3.54 (3H, s, 4-OCH₃), 3.79 (1H, br d, 3-H), 4.10 (1H, dd, 9-H), 4.11 (1H, br dd, 5-H), 4.47 (1H, dq, 5"-H), 4.59 (1H, d, 1'-H), 4.62 and 4.70 (each 1H, d, 4"-OCH₂C₆H₅), 4.90 (1H, d, 1"-H), 5.29 (1H, ddq, 15-H), 5.60 (1H, ddd, 13-H), 5.68 (1H, dd, 10-H), 6.03 $(1H, br dd, 12-H), 6.26 (1H, dd, 11-H), 7.3 \sim 7.4 (5H, m,$ 4"-OCH₂C₆H₅), 9.80 (1H, s, 18-H).

9,18-Di-*O-tert*-butyldimethylsilyl-3"-*O*-ethyl-4"-*O*-(3-methylbutyl)leucomycin V 3,18-Acetal (17)

To a stirred mixture of 6f (190 mg, 0.17 mmol) and oily sodium hydride (34 mg as 60%, 0.85 mmol) in dry DMF (1.0 ml) was added iodoethane (796 mg, 5.1 mmol). The resulting mixture was stirred at 45°C for 3 hours, then cooled to room temperature. After slowly adding H₂O (100 ml), the mixture was extracted with CHCl₃ (100 ml) twice. The organic layers were combined and washed with brine (100 ml) twice, dried and concentrated to give 114 mg of crude 12. To a solution of crude 12 in $CHCl_3$ (5.7 ml) was added mCPBA (26 mg, 0.15 mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous Na₂S₂O₃ (30 ml) and extracted with CHCl₃ (60 ml). The organic layer was successively washed with saturated aqueous NaHCO₃ (60 ml) twice and brine (60 ml) twice. Then, the organic layer was dried and concentrated to prepare 120 mg of crude 14. This oily product was charged on preparative TLC plates (Merck TLC 60F₂₅₄). After allowing the plates stand for 3 days, and then development was carried out for purification [CHCl3-MeOH (20:1)] to afford 45 mg (0.04 mmol, 26% overall 3 steps)

of 17.

MP $66 \sim 67^{\circ}$ C; $[\alpha]_{D} - 11^{\circ}$ (c 1.0, CH₃OH); FD-MS m/z 1028 (M+H)⁺; ¹H NMR δ 0.42 (1H, br dd, 7-H), 1.14 (3H, t, 3"-OCH₂CH₃), 1.23 (3H, s, 3"-CH₃), 1.31 (3H, d, 16-H), 1.44 (1H, dt, 17-H), 1.54 (1H, dd, 2"-Hax), 1.66 (1H, br d, 17-H), 2.21 (1H, d, 2"-Heq), 2.41 (1H, dd, 2-H), 2.45 (1H, t, 3'-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.74 (1H, d, 4"-H), 3.24 (1H, dq, 5'-H), 3.31 (1H, t, 4'-H), 3.33 (1H, dd, 2'-H), 3.44 (3H, s, 4-OCH₃), 3.45 and 3.50 (each 1H, dq, 3"-OCH₂CH₃), 3.54 and 3.66 (each 1H, dt, 4"-OCH₂CH₂CH(CH₃)₂), 4.05 (1H, br dt, 3-H), 4.19 (1H, dd, 9-H), 4.29 (1H, d, 1'-H), 4.46 (1H, dq, 5"-H), 4.57 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.84 (1H, d, 1"-H), 5.62 (1H, dt, 13-H), 5.73 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

9,18,2'-Tri-*O-tert*-butyldimethylsilyl-4"-*O*-(3-methylbutyl)-3"-*O-n*-propylleucomycin V 3,18-Acetal (13)

To a stirred mixture of **6f** (410 mg, 0.37 mmol) and oily sodium hydride (74 mg as 60%, 1.85 mmol) in dry DMF (820 μ l) was added 1-iodopropane (1.88 g, 11.0 mmol). The resulting mixture was stirred at 45°C for 4 hours, then cooled to room temperature. After slowly adding H_2O (200 ml), the mixture was extracted with CHCl₃ (200 ml) twice. The organic layers were combined and washed with brine (400 ml) twice, dried and concentrated to give 420 mg of crude **13**. This was purified by preparative TLC [CHCl₃-MeOH (20:1)] to afford 260 mg (0.23 mmol, 61%) of **13**.

MP 146 ~ 153°C; $[\alpha]_D$ – 21° (c 1.0, CHCl₃); FD-MS m/z 1156 (M+H)⁺; ¹H NMR δ 0.40 (1H, br dd, 7-H), 1.24 (3H, t, 3″-OCH₂CH₃), 1.33 (3H, d, 16-H), 2.22 (1H, d, 2″-Heq), 2.44 (1H, dd, 2-H), 2.62 (1H, dd, 2-H), 2.50 (6H, s, 3′-N(CH₃)₂), 2.77 (1H, d, 4″-H), 3.42 (3H, s, 4-OCH₃), 4.18 (1H, d, 1′-H), 4.22 (1H, br d, 3-H), 4.22 (1H, dd, 9-H), 4.44 (1H, dq, 5″-H), 4.62 (1H, br dd, 18-H), 4.80 (1H, ddq, 15-H), 4.92 (1H, d, 1″-H), 5.62 (1H, dt, 13-H), 5.76 (1H, dd, 10-H), 6.10 (1H, m, 11-H), 6.10 (1H, m, 12-H).

9,18-Di-*O-tert*-butyldimethylsilyl-4"-*O*-(3-methylbutyl)-3"-*O-n*-propylleucomycin V 3,18-Acetal (18)

To a solution of 13 (147 mg, 0.13 mmol) in CHCl₃ (6.5 ml) was added mCPBA (24 mg, 0.14 mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous Na₂S₂O₃ (30 ml) and extracted with CHCl₃ (60 ml). The organic layer was successively washed with saturated aqueous NaHCO₃ (60 ml) twice and brine (60 ml) twice. Then, the organic layer was dried and concentrated to afford 155 mg of crude 15. This oily product was charged on preparative TLC plates (Merck TLC 60F₂₅₄). After allowing the plates stand for 3 days, and then development was carried out for purification [CHCl₃-MeOH (20:1)] to afford 60 mg (0.06 mmol, 41% overall 2 steps) of 18.

MP 57~63°C; $[\alpha]_D$ -17° (*c* 1.0, CHCl₃); FD-MS m/z 1042 (M+H)⁺; ¹H NMR δ 0.88 (3H, t, 3″-OCH₂CH₂CH₃), 0.90 (6H, d, 4″-OCH₂CH₂CH(CH₃)₂),

1.22 (3H, d, 6"-H), 1.24 (3H, s, 3"-CH₃), 1.33 (3H, d, 16-H), 1.49 (1H, br dd, 17-H), 1.57 (1H, dd, 2"-Hax), 2.21 (1H, d, 2"-Heq), 2.43 (1H, dd, 2-H), 2.48 (1H, t, 3'-H), 2.58 (6H, s, 3'-N(CH₃)₂), 2.77 (1H, d, 4"-H), 3.25 (1H, dq, 5'-H), 3.27 (1H, br d, 4-H), 3.36 (1H, dd, 2'-H), 3.42 (2H, dt, 3"-OCH₂CH₂CH₃), 3.46 (3H, s, 4-OCH₃), 3.48 (1H, br dd, 5-H), 3.59 and 3.68 (each 1H, dt, 4"-OCH₂CH₂CH(CH₃)₂), 4.07 (1H, br d, 3-H), 4.21 (1H, dd, 9-H), 4.31 (1H, d, 1'-H), 4.46 (1H, dq, 5"-H), 4.59 (1H, br s, 18-H), 4.83 (1H, ddq, 15-H), 4.85 (1H, d, 1"-H), 5.64 (1H, ddd, 13-H), 5.75 (1H, dd, 10-H), 6.12 (1H, m, 11-H), 6.12 (1H, m, 12-H).

9,18-Di-*O-tert*-butyldimethylsilyl-4"-*O*-(3-methylbutyl)leucomycin V 3,18-Acetal (19)

To a solution of **6f** (1.00 g, 0.89 mmol) in CHCl₃ (50 ml) was added *m*CPBA (187 mg, 1.00 mmol). After stirring at room temperature for 5 minutes, the solution was dropped into 10% aqueous Na₂S₂O₃ (25 ml) and extracted with CHCl₃ (500 ml). The organic layer was successively washed with saturated aqueous NaHCO₃ (500 ml) twice and brine (500 ml) twice. Then, the organic layer was dried and concentrated to afford 1.01 g of crude **16**. A 220 mg portion of this oily product was charged on preparative TLC plate (Merck TLC 60F₂₅₄). After allowing the plates stand for 3 days, and then development was carried out for purification [CHCl₃-MeOH (20:1)] to afford 118 mg (67% overall 2 steps) of **19**.

MP 70 ~ 73°C; $[\alpha]_D$ — 6° (c 1.0, CH₃OH); EI-MS m/z 999 (M)⁺; ¹H NMR δ 0.44 (1H, br dd, 7-H), 0.99 (6H, d, 4″-OCH₂CH₂CH(CH₃)₂), 1.26 (3H, s, 3″-CH₃), 1.31 (3H, d, 16-H), 1.45 (1H, dt, 17-H), 1.53 (2H, m, 4″-OCH₂CH₂CH(CH₃)₂), 1.69 (1H, br d, 17-H), 1.70 (1H, m, 4″-OCH₂CH₂CH(CH₃)₂), 1.74 (1H, dd, 2″-Hax), 1.97 (1H, d, 2″-Heq), 2.53 (6H, s, 3′-N(CH₃)₂), 2.72 (1H, d, 4″-H), 3.44 (3H, s, 4-OCH₃), 3.64 (2H, m, 4″-OCH₂CH₂CH(CH₃)₂), 4.04 (1H, br dt, 3-H), 4.22 (1H, br d, 9-H), 4.26 (1H, d, 1′-H), 4.33 (1H, dq, 5″-H), 4.59 (1H, br dd, 18-H), 4.87 (1H, ddq, 15-H), 5.02 (1H, d, 1″-H), 5.63 (1H, dt, 13-H), 5.71 (1H, dd, 10-H), 6.11 (1H, m, 11-H), 6.11 (1H, m, 12-H).

3"-O-Ethyl-4"-O-(3-methylbutyl)leucomycin V (20)

Reaction of 17 gave 20 in 58% yield by a similar procedure to 3f.

MP 98~100°C; $[\alpha]_D$ -70° (c 1.0, CH₃OH); EI-MS m/z 799 (M)⁺; ¹H NMR δ 0.87 (6H, d, 4"-OCH₂CH₂-CH(CH₃)₂), 0.97 (3H, d, 19-H), 1.11 (3H, t, 3"-OCH₂-CH₃), 1.15 (3H, d, 6'-H), 1.21 (3H, d, 6"-H), 1.22 (3H, s, 3"-CH₃), 1.29 (3H, d, 16-H), 1.49 (2H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.55 (1H, dd, 2"-Hax), 1.65 (1H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.88 (1H, m, 8-H), 2.10 (1H, dt, 14-H), 2.20 (1H, br d, 2-H), 2.20 (1H, d, 2"-Heq), 2.31 (1H, br dd, 17-H), 2.38 (1H, t, 3'-H), 2.49 (1H, br d, 14-H), 2.55 (6H, s, 3'-N(CH₃)₂), 2.69 (1H, dd, 2-H), 2.73 (1H, d, 4"-H), 2.86 (1H, br dd, 17-H), 3.08 (1H, br d, 4-H), 3.16 (1H, dd, 2'-H), 3.24 (1H, dq, 5'-H), 3.40 (1H,

t, 4'-H), 3.42 and 3.47 (each 1H, dq, 3"-OCH₂CH₃), 3.53 (3H, s, 4-OCH₃), 3.56 and 3.64 (each 1H, dt, 4"-OCH₂CH₂CH(CH₃)₂), 3.77 (1H, br d, 3-H), 4.08 (1H, dd, 9-H), 4.09 (1H, br dd, 5-H), 4.41 (1H, dq, 5"-H), 4.56 (1H, d, 1'-H), 4.83 (1H, d, 1"-H), 5.27 (1H, ddq, 15-H), 5.59 (1H, ddd, 13-H), 5.66 (1H, dd, 10-H), 6.01 (1H, br dd, 12-H), 6.25 (1H, dd, 11-H), 9.80 (1H, br s, 18-H).

4"-O-(3-Methylbutyl)-3"-O-n-propylleucomycin V (21)

Reaction of 18 gave 21 in 58% yield by a similar procedure to 3f.

MP $88 \sim 93^{\circ}$ C; $[\alpha]_{D} -73^{\circ}$ (c 1.0, CH₃OH); SI-MS m/z 814 (M+H)⁺; ¹H NMR δ 0.87 (3H, t, 3"-OCH₂- CH_2CH_3), 0.89 (6H, d, 4"-OCH₂CH₂CH(CH₃)₂), 0.98 (3H, d, 19-H), 1.17 (3H, d, 6'-H), 1.22 (3H, d, 6"-H), 1.23 (3H, s, 3"-CH₃), 1.30 (3H, d, 16-H), 1.57 (1H, dd, 2"-Hax), 1.68 (1H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.91 (1H, m, 8-H), 2.12 (1H, dt, 14-H), 2.21 (1H, d, 2"-Heq), 2.22 (1H, br d, 2-H), 2.33 (1H, br dd, 17-H), 2.40 (1H, t, 3'-H), 2.51 (1H, br d, 14-H), 2.56 (6H, s, 3'-N(CH₃)₂), 2.70 (1H, dd, 2-H), 2.76 (1H, d, 4"-H), 2.88 (1H, br dd, 17-H), 3.10 (1H, brd, 4-H), 3.18 (1H, dd, 2'-H), 3.26 (1H, dq, 5'-H), 3.28 and 3.39 (each 1H, dt, 3"-OC H_2 -CH₂CH₃), 3.41 (1H, t, 4'-H), 3.55 (3H, s, 4-OCH₃), 3.58 and 3.66 (each 1H, dt, 4"-OC H_2 CH $_2$ CH(CH $_3$) $_2$), 3.79 (1H, br d, 3-H), 4.10 (1H, br dd, 5-H), 4.11 (1H, dd, 9-H), 4.41 (1H, dq, 5"-H), 4.58 (1H, d, 1'-H), 4.84 (1H, d, 1"-H), 5.29 (1H, ddq, 15-H), 5.61 (1H, ddd, 13-H), 5.68 (1H, dd, 10-H), 6.04 (1H, br dd, 12-H), 6.26 (1H, dd, 11-H), 9.80 (1H, br s, 18-H).

4"-O-(3-Methylbutyl)leucomycin V (22)

Reaction of 19 gave 22 in 45% yield by a similar procedure to 3f.

MP 94~97°C; $[\alpha]_D$ -69° (c 1.0, CH₃OH); EI-MS m/z 771 (M)⁺; ¹H NMR δ 0.90 (6H, d, 4"-OCH₂CH₂- $CH(CH_3)_2$, 1.01 (3H, d, 19-H), 1.20 (3H, d, 6'-H), 1.25 (3H, s, 3"-CH₃), 1.28 (3H, d, 6"-H), 1.31 (3H, d, 16-H), 1.52 (2H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.71 (1H, m, 4"-OCH₂CH₂CH(CH₃)₂), 1.75 (1H, dd, 2"-Hax), 1.91 (1H, m, 8-H), 1.98 (1H, d, 2"-Heq), 2.12 (1H, dt, 14-H), 2.23 (1H, brd, 2-H), 2.35 (1H, brdd, 17-H), 2.54 (6H, s, 3'-N(CH₃)₂), 2.70 (1H, dd, 2-H), 2.71 (1H, d, 4"-H), 2.83 (1H, br dd, 17-H), 3.08 (1H, br d, 4-H), 3.32 (1H, dq, 5'-H), 3.44 (1H, t, 4'-H), 3.51 (3H, s, 4-OCH₃), 3.63 $(2H, dt, 4''-OCH_2CH_2CH(CH_3)_2), 3.79 (1H, br d, 3-H),$ 4.12 (1H, br dd, 5-H), 4.12 (1H, dd, 9-H), 4.27 (1H, dq, 5"-H), 4.51 (1H, d, 1"-H), 5.00 (1H, d, 1"-H), 5.29 (1H, ddq, 15-H), 5.62 (1H, ddd, 13-H), 5.69 (1H, dd, 10-H), 6.03 (1H, br dd, 12-H), 6.27 (1H, dd, 11-H), 9.81 (1H, br s, 18-H).

Acknowledgments

We wish to thank Drs. S. INOUYE, S. SHIBAHARA and S. OMOTO for valuable discussions and encouragement during this study. We are also grateful to Dr. M. ARAAKE, Mrs. K. TOHYAMA and Miss M. IIDA for biological studies.

References

- 1) ŌMURA, S. (Ed.): Macrolide Antibiotics. Chemistry, Biology, and Practice. Academic Press Inc., 1984
- OKAMOTO, R.; T. FUKUMOTO, K. IMAFUKU, T. OKUBO, K. KIYOSHIMA, A. TAKAMATSU & T. TAKEUCHI: Screening for 16-membered macrolide-transforming microorganisms. J. Ferment. Technol. 57: 519 ~ 528, 1979
- Kirst, H. A.: New macrolides: expanded horizons for an old class of antibiotics. Journal of Antimicrobial Chemotherapy 28: 787~790, 1991
- SHOMURA, T.; S. SOMEYA, K. UMEMURA, M. NISHIO & S. MURATA: Metabolism of 9,3"-diacetylmidecamycin.
 I. The metabolic fate of 9,3"-diacetylmidecamycin.
 Yakugaku Zasshi (Japanese) 102: 781~795, 1982
- 5) KURIHARA, K.; K. AJITO, S. SHIBAHARA, T. ISHIZUKA, O. HARA, M. ARAAKE & S. OMOTO: Cladinose analogues of sixteen-membered macrolide antibiotics. I. Synthesis of 4-O-alkyl-L-cladinose analogues via glycosylation. J. Antibiotics 49: 582~592, 1996
- 6) AJITO, K.; K. KURIHARA, S. SHIBAHARA, O. HARA, A. SHIMIZU, M. ARAAKE & S. OMOTO: Cladinose analogues of sixteen-membered macrolide antibiotics. II. Preparation of pharmacokinetically improved analogues via biotransformations. J. Antibiotics 50: 92~95, 1997
- SAKAKIBARA, H.; O. OKEKAWA, T. FUJIWARA, M. AIZAWA & S. ŌMURA: Acyl derivatives of 16-membered macrolides. II. Antibacterial activities and serum lebels of 3"-O-acyl derivatives of leucomycin. J. Antibiotics 34: 1001~1010, 1981
- 8) SAKAKIBARA, H.; O. OKEKAWA, T. FUJIWARA, M. OTANI & S. ŌMURA: Anyl derivatives of 16-membered macrolides. I. Synthesis and biological properties of 3"-Opropionylleucomycin A₅ (TMS-19-Q). J. Antibiotics 34: 1011~1018, 1981
- AJITO, K.; K. KURIHARA, A. SHIMIZU, S. GOMI, N. KIKUCHI, M. ARAAKE, T. ISHIZUKA, A. MIYATA, O. HARA & S. SHIBAHARA (Meiji Seika Kaisha, LTD.): 16-

- Membered macrolide derivatives and process for producing the same. United States Patent 5,407,918, Apr. 18, 1995
- 10) ŌMURA, S. & A. NAKAGAWA: Chemical and biological studies on 16-membered macrolide antibiotics. J. Antibiotics 28: 401~433, 1975
- 11) SANO, H.; T. SUNAZUKA, H. TANAKA, K. YAMASHITA, R. OKACHI & S. ŌMURA: Chemical modification of spiramycins. III. Synthesis and antibacterial activities of 4"-sulfonates and 4"-alkylethers of spiramycin I. J. Antibiotics 37: 750~759, 1984
- 12) SANO, H.; T. SUNAZUKA, H. TANAKA, K. YAMASHITA, R. OKACHI & S. ŌMURA: Chemical modification of spiramycins. IV. Synthesis and in vitro and in vivo activities of 3",4"-diacylates and 3, 3", 4"-triacylates of spiramycin I. J. Antibiotics 37: 760~772, 1984
- 13) KIYOSHIMA, K.; M. SAKAMOTO, T. ISHIKURA, Y. FUKAGAWA, T. YOSHIOKA, H. NAGANAWA, T. SAWA & T. TAKEUCHI: Application of dibutyltin oxide method to regioselective acylation and alkylation of tylosin at C-4". Chem. Pharm. Bull. 37: 861~865, 1989
- 14) Мокімото, S.; Y. Misawa, H. Kondoh, Y. Watanabe & S. Omura: Chemical modification of erythromycins. V. Synthesis and antibacterial activities of 4"-O-metyl derivatives of erythromycin A 11,12-cyclic carbonate. J. Antibiotics 43: 566 ∼ 569, 1990
- 15) Tatsuta, K.; A. Tanaka, M. Kinoshita & S. Umezawa: Synthesis of cladinose analogues of carbomycin B. Chem. Lett. 1977: 769~772, 1977
- 16) SHIMIZU, A.; S. GOMI, K. AJITO, T. YAGUCHI, E. TANAKA, O. HARA & S. MIYADOH (Meiji Seika Kaisha, LTD.): Process for producing 3-deacylated derivative of 16membered macrolide antibiotic. United States Patent 5,219,736, Jun. 15, 1993
- 17) MORIMOTO, S.; Y. TAKAHASHI, Y. WATANABE & S. OMURA: Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A. J. Antibiotics 37: 187~189, 1984